<DOC>
	<DOCNO>NCT02387801</DOCNO>
	<brief_summary>To detect onset activity ixekizumab participant moderate-to-severe plaque psoriasis document use sequential photographic image .</brief_summary>
	<brief_title>A Study Early Activity Ixekizumab ( LY2439821 ) Moderate-to-Severe Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Present chronic moderatetosevere plaque psoriasis base confirm ( dermatologist ) diagnosis chronic plaque psoriasis least 6 month prior baseline Active psoriatic skin lesion plaque psoriasis ( Ps ) Are candidate phototherapy and/or systemic therapy Men must agree use reliable method birth control remain abstinent study least 12 week stop treatment Women must agree use reliable birth control remain abstinent study least 12 week stop treatment Are unable commit photography schedule duration study Have participate study interleukin 17 ( IL17 ) ( IL23 ) antagonist , include ixekizumab Serious disorder illness psoriasis Serious infection within last 3 month Breastfeeding nursing ( lactate ) woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>